**PMC: Board Resolution**

On January 18, 2024, Pharmedic Pharmaceutical Medicinal JSC announced Resolution No. 05/NQ-HDQT as follows:

Article 1: The Board of Directors approves the adjustment to production, business and financial plans for 2024 as follows:

* Total revenue: VND 492 billion (of which net revenue from main production and business activities is VND 486 billion).
* Total profit before tax: VND 91 billion.

Article 2: This Resolution takes effect from the date of its signing. Members of the Board of Directors, the Board of Management and related departments are responsible for the implementation of this Resolution.

On January 18, 2024, Pharmedic Pharmaceutical Medicinal JSC announced Resolution No. 06/NQ-HDQT as follows:

Article 1. The Board of Directors approves:

* The Annual General Meeting of Shareholders 2023 approves the dividend payment with the rate of 24% of par value per year.
* The dividend prepayment in cash for the first period of 2023 is 10% (paid on September 29, 2023).
* The dividend prepayment in cash for the second period of 2023 is 14% (expected payment in April 2024).
* The change of the plan for profit distribution and appropriation of funds in 2023 according to Article 4 of General Mandate No. 31/NQ-DHDCD-PMC dated April 22, 2023 and submitted to the Annual General Meeting of Shareholders 2024 as follows:
* "Remaining profits appropriated for the Development Investment Fund” section: Do not make an appropriation for the Development Investment Fund and transfer this remaining profit to the "Dividends paid to shareholders" section.
* “Dividend payment rate” section: Adjust to increase from 24% to 65% of charter capital.

Article 2. The Board of Directors approves the dividend payment rate at 24% in 2024 and submits it to the Annual General Meeting of Shareholders 2024.

Article 3: This Resolution takes effect from the date of its signing. Assign the General Manager to implement this Resolution.